Literature DB >> 20920650

Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus.

Roshanak Bagheri1, Atif N Qasim, Nehal N Mehta, Karen Terembula, Shiv Kapoor, Seth Braunstein, Mark Schutta, Nayyar Iqbal, Michael Lehrke, Muredach P Reilly.   

Abstract

Fatty acid-binding proteins (FABPs) 4 and 5 play coordinated roles in rodent models of inflammation, insulin resistance, and atherosclerosis, but little is known of their role in human disease. The aim of this study was to examine the hypothesis that plasma adipocyte and macrophage FABP4 and FABP5 levels would provide additive value in the association with metabolic and inflammatory risk factors for cardiovascular disease as well as subclinical atherosclerosis. Using the Penn Diabetes Heart Study (PDHS; n = 806), cross-sectional analysis of FABP4 and FABP5 levels with metabolic and inflammatory parameters and with coronary artery calcium, a measure of subclinical coronary atherosclerosis, was performed. FABP4 and FABP5 levels had strong independent associations with the metabolic syndrome (for a 1-SD change in FABP levels, odds ratio [OR] 1.85, 95% confidence interval [CI] 1.43 to 2.23, and OR 1.66, 95% CI 1.41 to 1.95, respectively) but had differential associations with metabolic syndrome components. FABP4 and FABP5 were also independently associated with C-reactive protein and interleukin-6 levels. FABP4 (OR 1.26, 95% CI 1.05 to 1.52) but not FABP5 (OR 1.13, 95% CI 0.97 to 1.32) was associated with the presence of coronary artery calcium. An integrated score combining FABP4 and FABP5 quartile data had even stronger associations with the metabolic syndrome, C-reactive protein, interleukin-6, and coronary artery calcium compared to either FABP alone. In conclusion, this study provides evidence for an additive relation of FABP4 and FABP5 with the metabolic syndrome, inflammatory cardiovascular disease risk factors, and coronary atherosclerosis in type 2 diabetes mellitus. These findings suggest that FABP4 and FABP5 may represent mediators of and biomarkers for metabolic and cardiovascular disease in type 2 diabetes mellitus.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20920650      PMCID: PMC3108486          DOI: 10.1016/j.amjcard.2010.06.028

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  27 in total

1.  Coronary artery calcification in type 2 diabetes and insulin resistance: the framingham offspring study.

Authors:  James B Meigs; Martin G Larson; Ralph B D'Agostino; Daniel Levy; Melvin E Clouse; David M Nathan; Peter W F Wilson; Christopher J O'Donnell
Journal:  Diabetes Care       Date:  2002-08       Impact factor: 19.112

2.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

3.  Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis.

Authors:  Liza Makowski; Jeffrey B Boord; Kazuhisa Maeda; Vladimir R Babaev; K Teoman Uysal; Maureen A Morgan; Rex A Parker; Jill Suttles; Sergio Fazio; Gökhan S Hotamisligil; MacRae F Linton
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

4.  Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein.

Authors:  G S Hotamisligil; R S Johnson; R J Distel; R Ellis; V E Papaioannou; B M Spiegelman
Journal:  Science       Date:  1996-11-22       Impact factor: 47.728

5.  Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes.

Authors:  Muredach P Reilly; Nayyar Iqbal; Mark Schutta; Megan L Wolfe; Monique Scally; A Russell Localio; Daniel J Rader; Stephen E Kimmel
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

6.  Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice.

Authors:  Jeffrey B Boord; Kazuhisa Maeda; Liza Makowski; Vladimir R Babaev; Sergio Fazio; MacRae F Linton; Gökhan S Hotamisligil
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

7.  Coronary artery calcification and cardiovascular risk factors: impact of the analytic approach.

Authors:  Muredach P Reilly; Megan L Wolfe; A Russell Localio; Daniel J Rader
Journal:  Atherosclerosis       Date:  2004-03       Impact factor: 5.162

8.  Role of the fatty acid binding protein mal1 in obesity and insulin resistance.

Authors:  Kazuhisa Maeda; K Teoman Uysal; Liza Makowski; Cem Z Görgün; Genichi Atsumi; Rex A Parker; Jens Brüning; Ann Vogel Hertzel; David A Bernlohr; Gökhan S Hotamisligil
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

9.  The prevalence of coronary artery calcium among diabetic individuals without known coronary artery disease.

Authors:  Julie Anne Hoff; Lauretta Quinn; Alexander Sevrukov; Rebecca B Lipton; Martha Daviglus; Daniel B Garside; Niraj K Ajmere; Sanjay Gandhi; George T Kondos
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

10.  The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults.

Authors:  E J Rhee; W Y Lee; C Y Park; K W Oh; B J Kim; K C Sung; B S Kim
Journal:  Eur J Endocrinol       Date:  2008-11-11       Impact factor: 6.664

View more
  31 in total

1.  Unsaturated fatty acids repress the expression of adipocyte fatty acid binding protein via the modulation of histone deacetylation in RAW 264.7 macrophages.

Authors:  Sara L Coleman; Young-Ki Park; Ji-Young Lee
Journal:  Eur J Nutr       Date:  2010-11-03       Impact factor: 5.614

2.  Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.

Authors:  Jane F Ferguson; Christine C Hinkle; Nehal N Mehta; Roshanak Bagheri; Stephanie L Derohannessian; Rhia Shah; Megan I Mucksavage; Jonathan P Bradfield; Hakon Hakonarson; Xuexia Wang; Stephen R Master; Daniel J Rader; Mingyao Li; Muredach P Reilly
Journal:  J Am Coll Cardiol       Date:  2012-02-21       Impact factor: 24.094

3.  Macrophage-specific transgenic expression of cholesteryl ester hydrolase attenuates hepatic lipid accumulation and also improves glucose tolerance in ob/ob mice.

Authors:  Jinghua Bie; Bin Zhao; Kathryn E Marqueen; Jing Wang; Barbara Szomju; Shobha Ghosh
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-03-06       Impact factor: 4.310

4.  Plasma levels of FABP4, but not FABP3, are associated with increased risk of diabetes.

Authors:  Luc Djoussé; J Michael Gaziano
Journal:  Lipids       Date:  2012-06-16       Impact factor: 1.880

5.  Fatty acid-binding protein 4 and incident heart failure: the Cardiovascular Health Study.

Authors:  Luc Djoussé; Traci M Bartz; Joachim H Ix; Jinesh Kochar; Jorge R Kizer; John S Gottdiener; Russell P Tracy; Dariush Mozaffarian; David S Siscovick; Kenneth J Mukamal; Susan J Zieman
Journal:  Eur J Heart Fail       Date:  2012-12-06       Impact factor: 15.534

6.  9- and 13-HODE regulate fatty acid binding protein-4 in human macrophages, but does not involve HODE/GPR132 axis in PPAR-γ regulation of FABP4.

Authors:  Venkat Vangaveti; Venkatesh Shashidhar; Fiona Collier; Jason Hodge; Catherine Rush; Usman Malabu; Bernhard Baune; Richard Lee Kennedy
Journal:  Ther Adv Endocrinol Metab       Date:  2018-02-27       Impact factor: 3.565

7.  Adipocyte-Specific Fatty Acid-Binding Protein (AFABP) and Chemerin in Association with Gestational Diabetes: A Case-Control Study.

Authors:  Maryam Mosavat; Mitra Mirsanjari; Bashir A Lwaleed; Maherah Kamarudin; Siti Zawiah Omar
Journal:  J Diabetes Res       Date:  2021-04-28       Impact factor: 4.011

8.  Fractalkine is a novel human adipochemokine associated with type 2 diabetes.

Authors:  Rachana Shah; Christine C Hinkle; Jane F Ferguson; Nehal N Mehta; Mingyao Li; Liming Qu; Yun Lu; Mary E Putt; Rexford S Ahima; Muredach P Reilly
Journal:  Diabetes       Date:  2011-05       Impact factor: 9.461

9.  Lipid chaperones and metabolic inflammation.

Authors:  Masato Furuhashi; Shutaro Ishimura; Hideki Ota; Tetsuji Miura
Journal:  Int J Inflam       Date:  2011-10-30

10.  Plasma fatty acid-binding protein 4, nonesterified fatty acids, and incident diabetes in older adults.

Authors:  Luc Djoussé; Owais Khawaja; Traci M Bartz; Mary L Biggs; Joachim H Ix; Susan J Zieman; Jorge R Kizer; Russell P Tracy; David S Siscovick; Kenneth J Mukamal
Journal:  Diabetes Care       Date:  2012-05-14       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.